SPIRIVA®* celebrates 10 years of ongoing commitment to patients and advancing clinical innovation in COPD
3 September 2012 | By Boehringer Ingelheim
SPIRIVA® is the most prescribed COPD maintenance treatment worldwide...
List view / Grid view
News
Novartis data at ERS shows efficacy of once-daily COPD portfolio versus comparators, further establishes dual-bronchodilator QVA149
3 September 2012 | By Novartis
Further data from the COPD clinical trial programs...
Phase III results: tiotropium* Respimat® significantly reduces exacerbations in asthma patients still symptomatic despite ICS/LABA treatment
3 September 2012 | By Boehringer Ingelheim
“These results exceeded our expectations..."
NextPharma appoints three new senior team members
30 August 2012 | By Virgo HEALTH
NextPharma Technologies Holding Limited, is delighted to announce the appointment of two key additions to its executive team...
Novartis QVA149 Phase III study meets primary endpoint in reducing exacerbations in COPD patients, filing in EU and Japan by end of year
30 August 2012 | By Novartis
SPARK met its primary endpoint...
New bottle for Ingelvac MycoFLEX® simplifies mixing with Ingelvac CircoFLEX®
30 August 2012 | By Boehringer Ingelheim
European approval for the MycoFLEX® Headspace bottle...
Abbott’s HUMIRA® (Adalimumab) approved in Europe for expanded treatment of Crohn’s Disease (CD)
30 August 2012 | By Abbott
Approval extends HUMIRA indication to include moderately active Crohn's Disease...
Novartis International BioCamp highlights global R&D reach to meet patient needs in emerging markets
29 August 2012 | By Novartis
Novartis welcomed its annual International Biotechnology Leadership Camp...
Large scale registry shows atrial fibrillation management is suboptimal and unequal around the world
29 August 2012 | By Boehringer Ingelheim
New one-year follow-up results from the global RE-LY AF registry...
Renishaw announces Raman seminars at the STFC, Rutherford Appleton Laboratory
28 August 2012 | By Renishaw
Following the success of the Inside Raman seminar last year...
Lundbeck receives approval from Health Canada for Treanda®
28 August 2012 | By H. Lundbeck A/S
Lundbeck announced that Health Canada has approved Treanda® following the success of the brand in both Europe and the US...
Changes to the Roche Corporate Executive Committee
28 August 2012 | By Roche
Daniel O’Day appointed new Head of Roche Pharma– Roland Diggelmann will assume the position Head of Roche Diagnostics...
Novartis drug Jakavi® first medication to receive European Commission approval to treat patients with myelofibrosis
28 August 2012 | By Novartis
Novartis received approval today from the European Commission for Jakavi®...
Pascal Soriot appointed Chief Executive Officer of AstraZeneca
AstraZeneca today announced that Pascal Soriot has been appointed as the company’s Chief Executive Officer. Pascal Soriot will take on his new responsibilities and join the AstraZeneca PLC Board as an Executive Director on 1 October 2012.
European Commission approves ZINFORO™ (ceftaroline fosamil) for adult patients with serious skin infections or community acquired pneumonia
28 August 2012 | By AstraZeneca
European Commission approves ZINFORO™...
